LTCHD, EDXC, PVEN, FB & Extended Watchlist

mCig, Inc. LTCHD

We put LTCHD up on yesterday afternoon’s Extended Watchlist, and are entering it into the discussion this morning as a new play on our marijuana-related stock radar. The company has recently transitioned to a new name, from Lifetech Industries to the current mCig. Along with that change, the company effected a 10-for-1 forward split.

For people who already owned shares prior to the restructuring, those shares were subject to a routine hold, which can take 3-5 days for the position to become free-trading. So we are on the lookout for a pullback this mid-week as that occurs, and people attempt to lock in profits by selling their shares into the market.

From there, we’ll be on the lookout for a bottom, and subsequent bounce.

The company falls under the marijuana stock category, as they are preparing for the rollout of their first mCig product within the next month. The company will be looking to capitalize on the legalization of marijuana in two states, as well as the growing popularity of “vapor pens” which vaporize cannabis concentrates for consumption.

BELLEVUE, WA, Aug 28, 2013 (Marketwired via COMTEX) — Lifetech Industries, Inc. (OTCBB: LTCHD), announces today that it has changed its name to mCig, Inc. and completed a forward stock split on a 10-for-1 basis.

On August 2, 2013, the Company’s Certificate of Incorporation was amended and restated to effect the name change and the forward stock split. The name change is part of an initiative led by incoming CEO Paul Rosenberg to reposition the company and its technology by launching a new consumer product, the mCig — a purpose built loose leaf eCig that will be launched next month.

mCig’s CEO, Paul Rosenberg, commented: “With the name change complete we can now focus on the next chapter of our business development targeting two long-term secular trends by developing consumer products that are exciting and disruptive. We will be updating our shareholders shortly with more information on our first product the mCig which will be launched in Q3 2013.”

The name change and the forward stock split were also approved by the Financial Industry Regulatory Authority (“FINRA”). The name change and forward split will be effective for trading purposes on the open of business on Thursday August 29, 2013. The new symbol will be (LTCHD) for 20 business days until September 27, 2013 when the symbol will change to (MCIG).

ENDEXX Corp. EDXC

EDXC is another medical marijuana play that we’ve been covering for quite some time. It also appeared in Friday’s report that revisited our interest in many cannabis stocks. Since that time, EDXC has traded from a low of .055 (Friday) to yesterday’s high of .097. That works out to a two-session move of 76%

Congrats to anyone who was able to take advantage of that timely alert, and be sure to check out that report containing all of our marijuana interests, as the entire sector was given a morale boost via last week’s US Department of Justice announcement that the federal government would not be interfering in individual states rights to make marijuana available to their citizens for both medical and recreational use.


Press Ventures, Inc. PVEN

PVEN has experienced an abnormal burst in volume over the past week or so, and yesterday’s volume exceeded the three days’ prior combined. Given that the stock wasn’t really trading up to that point, we have reason to suspect that PVEN could be the subject of an upcoming promotion. This out-of-the-blue volume explosion could be a result of front-loading, and so we are placing this stock on watch for any major price movements that could occur.

We also exercise the utmost caution when dealing with plays that have promotional activity going on behind the scenes, and this instance is no different.

Facebook, Inc. FB Options

FB has recently been pushing its 52-week highs (Hit 42.26 on Friday), so we are looking at how to capitalize on the trend via options trading. The 09/13 $41 Calls (closed at 1.57 yesterday) are of great interest to us, because if FB can breakout to $45 by next Friday, we could be looking at multi-bag gains from these contracts.

Extended Watchlist:
RMTI, INO, ZLCS, CYTK, STXS

Afternoon Update on Plandai Biotech (PLPL)

Plandai Biotechnology, Inc. PLPL
We’re sending out an update on PLPL this afternoon following this morning’s report. After trading as low as .55, the stock made its way back to .67, registering a 22% intraday gain in the process, and is currently holding support above the 50DMA.
In addition to an opportunity for a tidy profit during early trading, PLPL provided the public with a new press release that you can check out below. It eludes to an intellectual property licensing agreement, under the terms of which the company should be able to increase the effectiveness of its botanical extracts by a significant margin.

SEATTLE, WA, September 3, 2013 – (ACCESSWIRE) – Plandai Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid(R). Under the terms of the world license, Plandai has the exclusive right to use the Pheroid(R) technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use. >>> FULL PR

Some links for those who may have missed this morning’s newsletter:
PLPL Report
PLPL Video Chart

Extended Watchlist:
RENU, IWEB, LTCHD, NOK

Plandai Biotechnology, Inc. | PLPL | Added to Watchlist

Plandai Biotechnology, Inc. PLPL

Good morning traders, we hope everyone had an enjoyable long weekend. We’re bringing a new stock into the mix this morning in the agricultural/biotechnology business. The company’s main holding consists of an 8000+ acre plantation located in Mpumalanga, South Africa (2000 acres of which are used for production of green tea), and a recent licensing and raw-material provision agreement has it aligned with Phyto Nutricare.

This partnership will facilitate the delivery of Phytofare™ branded botanical extracts and nutraceuticals to the international marketplace. Some of the highlights of the Phytofare line include:

  • Patented Formula – The products are a result of years of research into plant extracts.
  • Consist of extracts taken from LIVING plant material, setting Phytofare™ apart.
  • Improved integration into bloodstream, known as “bio-availability” (More on that below)
  • Contain Nano-Sized Particles for maximum cell permeability.
  • Unique Isomeric Properties (Isomers are particles with the same molecular properties as a given element, while having different chemical properties.)

Plandai, through Phytofare™, has a chance at making a real dent in the green tea extract market. Currently, even high-purity green tea extracts on today’s market have been tested and found to be lacking in bio-availability, that is only a small amount (≤10%) of the essential nutrients are absorbed into the system. However, in USDA tests, Phytofare extracts have demonstrated improved bio-availability levels to as much as 60-80% which obviously is a dramatic increase in potency.

This apparent leap forward in green tea extract technology should allow PLPL to make its mark on the cosmeceutical, health & wellness, as well as the food & beverage industries. After all, who among current green tea extract consumers wouldn’t want the benefit of the same products they’ve come to appreciate having exponentially increased effectiveness? For this reason, we’re anxious to include PLPL on our watchlists moving forward.

We’ve also prepared a video of the PLPL chart to point out some of the highlights:

Additionally, the good folks over at BARCHART.COM currently give PLPL a 72% Overall “Buy” Rating, Including a 100% Rating on Long-Term Indicators.

More Info @

http://www.plandaibiotech.com/